SciELO - Scientific Electronic Library Online

 
vol.29 suppl.2Infecciones más comunes en el paciente trasplantadoTrasplante celular y terapia regenerativa con células madre índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Anales del Sistema Sanitario de Navarra

versión impresa ISSN 1137-6627

Resumen

SADABA, B.. Monitoring and secondary effects of immunosuppressants in the transplant. Anales Sis San Navarra [online]. 2006, vol.29, suppl.2, pp.207-218. ISSN 1137-6627.

The success of organ transplants and their consideration as a clearly established treatment in some indications is due to the development of immunosuppressant drugs. While it was not the first of the drugs to be employed, the introduction of cyclosporin in the 1980s in immunosuppressant treatment made possible an increase in the number of transplants and the success of this practice. From then onwards, immunosuppression has been based on the use of a combination of drugs, initially cyclosporin, corticoids and azathioprine. In recent years new drugs have been introduced that have opened up the possibilities of treatment. But many pending questions remain, due to the toxicity associated with their use and the possibility of interaction with other drugs, which complicates their use and can compromise the prognoses of these patients. Calcineurin inhibitors and mTOR are the drugs involved with greater frequency in interactions with other drugs, which makes it necessary to anticipate this possibility when the concomitant medication is changed.

Palabras clave : Immunosuppressants; Therapeutic level; Medication interactions.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons